NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories declared a quarterly dividend on Friday, December 13th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.36 per share on Friday, February 14th. This represents a $1.44 annualized dividend and a dividend yield of 1.57%. The ex-dividend date is Tuesday, January 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.32. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings data on Wednesday, January, 22nd. The healthcare product maker reported $0.95 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.95. The healthcare product maker had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.26 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. Abbott Laboratories's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.81 earnings per share. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 22nd 2020. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories issued an update on its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share (EPS) guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.60.

16 equities research analysts have issued twelve-month price objectives for Abbott Laboratories' shares. Their forecasts range from $81.00 to $101.00. On average, they expect Abbott Laboratories' share price to reach $91.27 in the next twelve months. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for Abbott Laboratories.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Headlines about ABT stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Abbott Laboratories earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the healthcare product maker a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Abbott Laboratories.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Walt Disney (DIS), Home Depot (HD), NVIDIA (NVDA), Pfizer (PFE), Intel (INTC) and Micron Technology (MU).

Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.11%), Gateway Investment Advisers LLC (0.05%), Hexavest Inc. (0.04%), Nisa Investment Advisors LLC (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.04%) and Candriam Luxembourg S.C.A. (0.04%). Company insiders that own Abbott Laboratories stock include Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Norris Perne & French LLP MI, OLD National Bancorp IN, Artemis Investment Management LLP, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Candriam Luxembourg S.C.A., Huntington National Bank and Hexavest Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Garnet Equity Capital Holdings Inc., Janney Montgomery Scott LLC, Rockland Trust Co., United Services Automobile Association, Donaldson Capital Management LLC, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund and Advisors Capital Management LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $91.86.

Abbott Laboratories has a market capitalization of $162.45 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.